Regeneron Pharmaceuticals revenue
Regeneron Pharmaceuticals's revenue was $14.34bn in fiscal 2025, up 1.0% on the year before. Since fiscal 2009 ($379m) it has grown at a compound 25.5% a year. Over the last twelve months it was $16.90bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.4 | 0.5 | 0.4 | 1.4 | 2.1 | 2.8 | 4.1 | 4.9 | 5.9 | 5.1 | 6.6 | 8.5 | 16.1 | 12.2 | 13.1 | 14.2 | 14.3 | 16.9 |
| Growth on the year before | — | +21.0% | −2.9% | +209.2% | +52.7% | +34.0% | +45.5% | +18.4% | +20.8% | −12.4% | +27.4% | +29.6% | +89.1% | −24.3% | +7.8% | +8.3% | +1.0% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | 4.9 | 6.2 | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | 95.4% | 93.9% | — | — | — | — | — | — | — |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Collaboration Revenue | $7.3B | ▲ 21.0% |
| Products | $6.3B | ▼ 17.3% |
| LIBTAYO Net Product Sales | $1.5B | ▲ 19.3% |
| Other | $703M | ▲ 36.4% |
| Other Products | $10.1M | — |
These categories overlap or exclude eliminations, so shares aren't shown.
From Regeneron Pharmaceuticals's 10-K filed February 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Regeneron Pharmaceuticals | $16.90bn | 18.6% | 8.9% |
| Vertex Pharmaceuticals | $12.59bn | 10.2% | 9.8% |
| Biogen | $10.30bn | 2.3% | 1.0% |
| Gilead Sciences | $30.99bn | 6.5% | 4.2% |
| Amgen | $38.09bn | 9.1% | 12.7% |
| Incyte | $6.01bn | 24.9% | 18.5% |
Compare with peers
Head to head: REGN vs VRTXBIIB vs REGNGILD vs REGNAMGN vs REGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies